Core Viewpoint - Darentang (600329.SH) reported a significant decline in total operating revenue for the first three quarters of 2025, while net profit attributable to shareholders saw substantial growth [1] Financial Performance - Total operating revenue for the first three quarters reached 3.67 billion yuan, representing a year-on-year decrease of 34.59% [1] - Net profit attributable to shareholders was 2.152 billion yuan, showing a year-on-year increase of 167.73% [1] - Basic earnings per share were reported at 2.8 yuan [1] Dividend Announcement - The company proposed a cash dividend of 24.5 yuan (including tax) for every 10 shares to all shareholders [1]

津药达仁堂集团股份有限公司（以下简称"公司"）于2025年10 月29日召开了2025年第六次董事会会议，审议通过了续聘中审华会计 师事务所（特殊普通合伙）为公司2025年度境内审计师，续聘胡官陈 有限责任合伙会计师事务所（FKT）为公司2025年度境外审计师，并 提请股东大会授权董事会确定其聘金的议案。 一、拟聘任境内审计师的基本情况 （一）机构信息 证券代码：600329 证券简称：达仁堂 编号：临 2025-038 号 津药达仁堂集团股份有限公司 关于续聘审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1. 基本信息 机构名称：中审华会计师事务所（特殊普通合伙） 成立日期：2000 年 9 月 19 日 组织形式：特殊普通合伙 注册地址：天津经济技术开发区第二大街 21 号 4 栋 1003 室 首席合伙人：黄庆林 2024 年度末合伙人数量：100 人 2024 年度末注册会计师人数：550 人 2024 年挂牌公司审计客户家数 77 家，前五大主要行业： | 行业代码 | 行业门类 | 行业大类 | ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-037 号 津药达仁堂集团股份有限公司 关于修改《公司章程》并办理工商变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》、中国证券监督管理委员会《上市公司章程指引》（2025 年 3 月修订）等相关法律法规、规范性文件的规定，结合公司管理实际，公司拟取消 监事会，原监事会法定职权由董事会审计委员会行使，并对《公司章程》进行相 应修订。修订的《公司章程》相关条款如下： | 修订前 | 修订后 | 修订 | | --- | --- | --- | | | | 类型 | | 第七条 公司章程对公司及其股东、 | 第七条 公司章程对公司及其股东、 | | | 董事、监事、总经理和其他高级管理人员 | 董事、总经理和其他高级管理人员均有约 | | | 均有约束力；前述人员均可以依据公司章 | 束力；前述人员均可以依据公司章程提出 | | | 程提出与公司事宜有关的权利主张。 | 与公司事宜有关的权利主张。 | | | 股东可以依据公司章程起诉公司；公 ...

关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 证券代码：600329 证券简称：达仁堂 公告编号：2025-040 号 津药达仁堂集团股份有限公司 召开的日期时间：2025 年 12 月 15 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 股东大会召开日期：2025年12月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 15 日 至2025 年 12 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2025 年 10 月 17 日发出会议通知，并于 2025 年 10 月 29 日以现场结合通讯方式召开了 2025 年第四次监事会会议，会议应到 监事 3 名，实到监事 3 名。本次会议召开符合公司章程的有关规定， 经与会监事认真审议，形成如下决议： 一、审核公司 2025 年第三季度报告无误，并发表审核意见如下： 证券代码：600329 证券简称：达仁堂 编号：临 2025-036 号 津药达仁堂集团股份有限公司 2025 年第四次监事会决议公告 1．公司 2025 年第三季度报告的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定； 2．公司 2025 年第三季度报告的内容和格式符合中国证监会和证 券交易所的各项规定，所包含的信息从各个方面真实地反映出公司本 季度的经营管理和财务状况等事项； 2025 年 10 月 31 日 2 二、审核公司 2025 年前三季度利润分配预案无误。 监事会认为公司 2025 年前三季度利润分配预案符合中国证监会、 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-035 号 津药达仁堂集团股份有限公司 2025 年第六次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司于 2025 年 10 月 17 日发出会议通 知，并于 2025 年 10 月 29 日以现场结合通讯方式召开了 2025 年第六 次董事会会议。本次会议应参加董事 9 人，实参加董事 9 人。会议召 开符合《公司法》、《证券法》和《公司章程》有关召开董事会会议的 规定。会议形成如下决议： 一、审议通过了公司 2025 年中国准则第三季度报告与国际准则 的第三季度报告。 据本公司董事会全体成员及管理层所知，没有任何其他信息将致 使该报告不确实或具有误导性。 本议案已经公司董事会审计委员会审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票 二、审议通过了《关于修订<公司章程>并办理工商变更的议案》。 （详见临时公告 2025-037 号） 经董事会审阅，认为本次对《公司章程》中取消监事会，原监事 会法定职权由 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-039 号 津药达仁堂集团股份有限公司 2025 年前三季度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 截至 2025 年 9 月 30 日，本公司母公司报表期末未分配利润为 6,577,352,140.60 元人民币（未经审计）。经董事会决议，公司拟以实 施权益分派股权登记日登记的总股本为基数，实施 2025 年前三季度 利润分配。本次利润分配方案如下： 2025 年三季度末，公司拟进行利润分配，以实施权益派息股权 登记日总股本为基数，向全体股东每 10 股派发现金红利 24.50 元人 民币（含税）。截至 2025 年 9 月 30 日，公司总股本 770,094,356 股（其 中，A 股 570,094,356 股，S 股 200,000,000 股），以此计算合计拟派 发现金红利 1,886,731,172.20 元人民币（含税）。本次公司现金分红 占公司2025 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 1,019,342,255.45, a decrease of 38.08% year-on-year[4] - Total profit for the quarter reached CNY 253,188,070.04, an increase of 44.05% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 224,559,220.11, reflecting a year-on-year increase of 53.66%[4] - Basic earnings per share for the quarter were CNY 0.30, an increase of 57.89% compared to the same period last year[5] - Total profit for the year-to-date increased by 172.92%, primarily due to the sale of a 12% stake in a joint venture, generating a disposal gain of 1.54 billion RMB after tax[10] - Net profit for the first three quarters of 2025 reached CNY 2,146,216,262.92, compared to CNY 793,134,205.47 in 2024, reflecting an increase of approximately 171.5%[19] - Operating profit for the first three quarters of 2025 was CNY 2,522,594,956.81, significantly higher than CNY 919,432,930.61 in the previous year, marking an increase of around 174.3%[19] - The net profit attributable to the parent company shareholders for the first three quarters of 2025 is CNY 2,152,182,184.52, compared to CNY 803,855,815.93 in the same period of 2024, representing a significant increase[20] - The total comprehensive income for the first three quarters of 2025 is CNY 2,145,311,321.48, up from CNY 792,454,029.76 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 2.80, compared to CNY 1.04 in 2024, indicating a strong performance improvement[20] Cash Flow - The cash flow generated from operating activities amounted to CNY 102,588,569.58, a significant increase of 727.70% year-on-year[4] - The net cash flow from operating activities increased by 727.70% for the current reporting period, mainly due to a rise in cash received from sales of goods and services[10] - Cash inflows from operating activities for the first three quarters of 2025 amount to CNY 3,640,002,364.59, down from CNY 6,200,789,712.62 in 2024[21] - The net cash flow from operating activities for the first three quarters of 2025 is CNY 590,329,947.27, slightly up from CNY 567,609,005.34 in 2024[21] - Cash outflows from investing activities for the first three quarters of 2025 total CNY 5,010,758,565.34, compared to CNY 1,391,606,362.08 in 2024, indicating increased investment activity[22] - The net cash flow from investing activities for the first three quarters of 2025 is -CNY 1,506,491,600.39, worsening from -CNY 1,175,618,836.51 in 2024[22] - The net cash flow from financing activities for the first three quarters of 2025 is -CNY 979,528,249.55, compared to -CNY 31,519,702.29 in 2024, reflecting a significant increase in cash outflows[22] - The ending cash and cash equivalents balance as of the end of the third quarter of 2025 is CNY 1,048,684,858.24, down from CNY 1,357,743,974.78 in 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,585,156,807.98, representing a 7.58% increase from the end of the previous year[5] - Total assets as of September 30, 2025, were CNY 11,585,156,807.98, compared to CNY 10,768,625,044.29 at the end of 2024, reflecting an increase of about 7.6%[15] - Total liabilities decreased to CNY 2,561,059,550.26 as of September 30, 2025, from CNY 2,918,688,717.32 at the end of 2024, a decline of approximately 12.3%[16] - Shareholders' equity attributable to the company was CNY 9,009,343,064.30, up 14.86% from the previous year-end[5] - Shareholders' equity increased to CNY 9,024,097,257.72 as of September 30, 2025, compared to CNY 7,849,936,326.97 at the end of 2024, representing an increase of about 14.9%[16] Product Sales - The sales revenue of the main product, Su Xiao Xin Xin Wan, was CNY 1.716 billion, up 13.34% year-on-year[6] - The sales revenue of Qing Yan Di Wan reached CNY 376 million, marking a year-on-year growth of 38.61%[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 58,613[12] - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 331,120,528 shares, accounting for 42.997% of total shares[12] Accounting and Reporting Changes - The company plans to divest its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd., which will impact revenue recognition in future reports[6] - Operating revenue for the current reporting period decreased by 38.08%, primarily due to changes in the scope of consolidation, as Tianjin Zhongxin Pharmaceutical Co., Ltd. is no longer included in the data[10] - The company will not apply new accounting standards starting from 2025, as stated in the announcement[23]

津药达仁堂集团股份有限公司 章 程 二零二五年十月二十九日 | | | | 第一章 | 总则………………………………………………………………………3 | | --- | --- | | 第二章 | 经营宗旨和范围…………………………………………………………4 | | 第三章 | 股份和注册资本…………………………………………………………5 | | 第四章 | 减资和购回股份…………………………………………………………9 | | 第五章 | 购买公司股份的财务资助………………………………………………12 | | 第六章 | 股份转让…………………………………………………………………13 | | 第七章 | 股票和股东名册…………………………………………………………14 | | 第八章 | 股东的权利和义务………………………………………………………18 | | 第九章 | 股东大会…………………………………………………………………23 | | 第十章 | 类别股东表决的特别程序………………………………………………38 | | 第十一章 | 党的组织…………………………………………………………40 | | 第十二章 ...

Market Performance - The market experienced a rebound last week, with the CSI Xinhua National Brand Index rising by 4.14% to 2037.67 points [1][2] - The Shanghai Composite Index increased by 2.88%, the Shenzhen Component Index by 4.73%, the ChiNext Index by 8.05%, and the CSI 300 Index by 3.24% [2] Strong Stock Performances - Notable strong performers included: - Zhongji Xuchuang (up 32.23%) - Shiyuan Technology (up 14.54%) - Sunshine Power (up 14.37%) [2] - Other stocks with significant gains included: - Anji Technology and Wowo Bio (both up over 10%) - SMIC and Zhaoyi Innovation (both up over 9%) [2] Year-to-Date Stock Performance - Since the beginning of the second half of the year, Zhongji Xuchuang has surged by 239.03%, leading the gains [3] - Sunshine Power has increased by 145.06%, while other stocks like Lanke Technology and Yiwei Lithium Energy have risen over 70% [3] Market Outlook - According to Fangzheng Fubang Fund, liquidity remains a crucial driver for market development, and future capital inflow will significantly impact market trends [4] - The fund suggests focusing on sectors with solid fundamentals and reasonable valuations, rather than chasing high-performing stocks with poor earnings [4] - Long-term investment opportunities may lie in technology companies with real technological barriers that align with national strategies [4] - Kangmand Capital anticipates a volatile market in the short term due to uncertainties, but the core logic for an upward trend remains unchanged [4] - Xingshi Investment notes that positive incremental information could stabilize market expectations and emotions, with a potential shift in economic momentum towards technology and consumption [4]